Selexipag Titration Pack Kit
NDC Package 70710-1653-7
Package Information
Selexipag Titration Pack (selexipag) kits is selexipag is used to treat high blood pressure in the lungs (pulmonary arterial hypertension-PAH). This formulation utilizes a kit delivery system. Marketed by Zydus Pharmaceuticals (usa) Inc., this product is identified by NDC 70710-1653 and is authorized under FDA application ANDA214302.
Identification & Billing
- RxCUI: 1729007 - selexipag 1000 MCG Oral Tablet
- RxCUI: 1729007 - selexipag 1 MG Oral Tablet
- RxCUI: 1729027 - selexipag 1200 MCG Oral Tablet
- RxCUI: 1729027 - selexipag 1.2 MG Oral Tablet
- RxCUI: 1729031 - selexipag 1400 MCG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70710 - Zydus Pharmaceuticals (usa) Inc.
- 70710-1653 - Selexipag Titration Pack
- 70710-1653-7 - 1 KIT in 1 CARTON * 1 BOTTLE in 1 CARTON / 140 TABLET, FILM COATED in 1 BOTTLE (70710-1551-8) * 1 BOTTLE in 1 CARTON / 60 TABLET, FILM COATED in 1 BOTTLE (70710-1554-6)
- 70710-1653 - Selexipag Titration Pack
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70710-1653-7 identifies a specific commercial package of 1 kit in 1 carton * 1 bottle in 1 carton / 140 tablet, film coated in 1 bottle (70710-1551-8) * 1 bottle in 1 carton / 60 tablet, film coated in 1 bottle (70710-1554-6) of Selexipag Titration Pack, a human prescription drug labeled by Zydus Pharmaceuticals (usa) Inc.. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Pharmaceuticals (usa) Inc. on February 14, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Selexipag is used to treat high blood pressure in the lungs (pulmonary arterial hypertension-PAH). It is used to help slow down worsening of PAH and to decrease the chance of needing treatment in a hospital. Selexipag works by making it easier for blood to flow through the arteries in your lungs. This effect helps increase your ability to exercise.
How is this Zydus Pharmaceuticals (usa) Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70710165307. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.